Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Boyd Quinnell, CPA, MBA, to the Trethera Board of Directors as an independent director.
January 18, 2023
· 4 min read